Lixte Biotechnology provides update on recent activities, developments

LIXTE Biotechnology (LIXT) provided an update on the Company’s recent activities. “We are encouraged by the growing interest shown by major pharmaceutical companies in our proprietary compound, LB-100, as demonstrated by their support in clinical trial collaborations,” said Bas van der Baan, LIXTE’s President and Chief Executive Officer. Recent Company Highlights: Collaboration with the Netherlands Cancer Institute, supported by Roche (RHHBY), to conduct a new clinical trial in immune therapy for unresponsive metastatic colorectal cancer. Jan Schellens, M.D., Ph.D., joined LIXTE as Chief Medical Officer effective August 1, 2024. New pre-clinical data in the journal EMBO Reports shows that LIXTE’s lead compound, LB-100, can turn immunologically “cold” tumors “hot,” potentially enhancing the benefit of immunotherapy. LIXTE will present at two upcoming investor conferences: the 2004 Summit Summer 2024 Virtual Conference, August 20, 2024, and the H.C. Wainwright 26th Annual Global Investor Conference, September 9-11, 2024.